Ozmpic Novo Nordisk to reduce 11 % of the workforce

Novo Nordisk, Titan, the Danish pharmacist behind Ozzic, revealed today a comprehensive global restructuring plan to reduce approximately 11 % of the total workforce, as it is flooded with market weight loss.

Novo Nordisk faces an increasing competition from Eli Lily, the American company behind Monjo, and a new wave of licensed alternatives. By reducing about 9,000 jobs – more than half of them in Denmark – the company expects an annual savings of about $ 1.25 billion by the end of 2026, with money allocating for investment in diabetes areas and obesity treatment.

“Our markets are developing, especially in obesity, as it has become more competitive and consumed. Our company must also develop,” said Mike Dosdar, President of Novo Nordisk and CEO of the Declaration. This means accelerating a “performance-based culture” and determining investment priorities “as it will have the largest effect-behind the leading fields of treatment. The company said that savings will be re -directed to growth opportunities in diabetes and obesity, including both commercial implementation initiatives and research and development programs.

“Novo Nordsek, who has grown fat on the spoils of weight loss medications, was feeling the effects of competitors walking in space. Understanding about the American customs tariff was also a danger that still casts a shadow on the industry,” He said The guardian. “By becoming a smaller machine, Novo hopes to redirect more funding and development to support the product pipeline.”

The workforce reduction also indicates a dramatic reflection of the recruitment Noura, which has witnessed the growth of the number of employees by 75 % over the past five years, with the popularity of weight loss medications. Workers restore the number of employees to early 2014 levels, Redburn Atlantic Simon Baker He said Reuters.

Novo Nordisk is estimated that it will bear the costs of one time restructuring at about $ 1.25 billion, largely during the third quarter of this year. The company has reduced operating profit growth forecast for 2025 from 10 to 16 % to 4-10 % due to the effect of restructuring.

This announcement came only weeks in Dosdar as CEO. He pointed out that this restructuring is one of his first main works to re -put the company to achieve success in the long run.

While Novo Nordsk shares fell after warnings in the previous profits, investors responded positively to the restructuring plan: their shares listed in the Danish list increased by about 3 %, while US shares rose about 1.7 % in pre -market trading.